Stilla Technologies, Yuzi Holdings and TusPark donate digital PCR Naica™ Systems to help fight coronavirus outbreak in China

A Franco-Chinese collaboration to better detect the virus and monitor its mutations

Stilla Technologies, a leading provider of pioneering digital PCR (dPCR) solutions for high-precision genetic analyses, just announced it will be joining an initiative led by Yuzi Holdings and TusPark Science & Technology Service Group (TusPark) to donate two Naica Systems to City of Zhengzhou and City of Xinyang[1], in China, to help them better detect the coronavirus and monitor its mutations. As part of the initiative, Cycloud/Apexbio, Stilla’s distributors and business partners in China, will offer technical support, reagents and kits.

“Since the beginning of the outbreak and for several weeks now, the Chinese Center for Disease Control and Prevention has been working with the Naica System, both at the national level and in the city of Shiyan, in Hubei Province. We strongly believe that the Naica System will help strengthen the fight against the epidemic,” said Daniel Wang, CEO of Tuspark Europe, the European subsidiary of TUS-Holdings.

Rémi Dangla, Cofounder and CEO of Stilla Technologies said: “We are extremely proud to join TusPark in the donation initiative. It is a unique opportunity to support the fight against the epidemic directly where the most urgent needs are.”

Currently, the main method for diagnosing infections uses quantitative PCR (qPCR), a method for which the sensitivity/detection rate remains to be established. An insufficient sensitivity may hamper ongoing efforts to prevent and contain the epidemic, as researchers strive to track the virus mutation rate and its influence on the disease.

Digital PCR is an alternative detection method known for its higher sensitivity, accuracy, resolution and tolerance, compared to standard quantitative PCR.

The Naica System, the latest generation of digital PCR platforms developed by Stilla Technologies, combined with Cycloud/Apexbio’s Covid-2019 detection kits, can provide fast, accurate and reliable DNA/RNA detection of the virus and its mutations.

In January 2020, Stilla Technologies raised 20 million euros in a Series-B funding round led by TUS-Holdings, the China-Luxembourg Innovative Investment Fund established by Yuzi Holdings and TusPark, alongside Illumina Ventures, the global partner of TusPark and other European funds.

The biotech and emerging In Vitro Diagnostics (IVD) market is an investment priority for TusPark, which has directly or indirectly invested in more than 20 high-tech companies. Throughout the coronavirus outbreak, several of TusPark’s portfolio companies, including AccBio, Tus-Health, LifeHealthCare and ZechengBio, have been involved in medical testing for the development of detection kits. As an advanced medical equipment supplier, Stilla Technologies will continue working with other partners to fight against SARS-CoV-2.

[1]   Zhengzhou City and Xinyang City, which are located near Hubei Province, the epicenter of the outbreak, are also strongly impacted by the disease.

Stilla Technologies, Yuzi Holdings and TusPark donate digital PCR Naica™ Systems to help fight coronavirus outbreak in China
Bayer, Meiogenix collaborate to accelerate agricultural innovation through the development of unique technologies
Other news
Median Technologies records its best quarterly performance and joins forces with biopharmaceutical companies in the fight against Covid-19.
HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies
Hungary and the Netherlands approve Lipiodol® Ultra Fluid for hysterosalpingography in women undergoing infertility workup
Alexis RIDEAU appointed Chief Executive Officer of DEINOVE with the ambition to strengthen the Company’s strategy for innovation and partnerships